Drug repositioning, the assignment of new therapeutic purposes to known drugs, is an
established strategy with many repurposed drugs on the market and many more at …

Drug repositioning aims to find new indications for existing drugs in order to reduce drug
development cost and time. Currently, there are numerous stories of successful drug …

The discovery of new scaffolds and chemotypes via high-throughput screening is tedious
and resource intensive. Yet, there are millions of small molecules commercially available …

Trypanosomatids are a group of flagellated unicellular eukaryotes, causing serious human
diseases including Chagas disease (Trypanosoma cruzi), slee** sickness (Trypanosoma …

We have developed a new system, ProBiS-Dock, which can be used to determine the
different types of protein binding sites for small ligands. The binding sites identified this way …

Chagas disease, caused by the parasite Trypanosoma cruzi, affects millions of people in
South America. The current treatments are limited, have severe side effects, and are only …

Drug repositioning identifies new indications for known drugs. Here we report repositioning
of the malaria drug amodiaquine as a potential anti-cancer agent. While most repositioning …

Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects nearly eight million people
worldwide. There are currently only limited treatment options, which cause several side …

Drug discovery is usually focused on a single protein target; in this process, existing
compounds that bind to related proteins are often ignored. We describe ProBiS plugin …

Introduction: The success of binding site comparisons in drug discovery is based on the
recognized fact that many different proteins have similar binding sites. Indeed, binding site …